Source: Zacks Investment Research News Agency
1 month ago•
Stock Medium Importance
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Related Symbols 1
VNDA VNDA
Source: Zacks Investment Research
Visit Source
0 0 0
Comment
Comments
0
No comments yet
Be the first person to comment on this news item.